美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Militia Long/Short Equity ETF

38.55

-0.1788-0.46%

成交量：2.98萬

成交額：114.35萬

市值：3.54億

市盈率：- -

高：38.80

開：38.80

低：38.30

收：38.73

52周最高：39.80

52周最低：30.66

股本：917.00萬

流通股本：917.00萬

量比：1.36

換手率：0.32%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

日本橡膠期貨受空頭回補及非洲出口限制雙重因素提振走高。

和黃醫藥：凡瑞格拉替尼II期研究ORR達42.50%

南方财经网

治療「癌症之王」，RAS抑制劑的「新搭檔」浮出水面

基石藥業公布一個指標：市值蒸發40%

人類抗癌關鍵性突破！RedMed新療法讓「癌王」患者生存期翻倍，死亡風險降低60%

华尔街见闻

核心管線數據利空基石藥業股價大跌

21世纪经济报道

核心管線數據利空，基石藥業股價大跌超32%

21世纪经济报道

Alpha Tau新型放射療法在美國完成臨床試驗患者招募

环球市场播报

核藥「狂飆」：2026年中外巨頭激戰300億美元藍海

21世纪经济报道

營收按年下降33.8%，基石藥業押注三抗管線進展如何？

21世纪经济报道

科賽優®在華獲批用於治療伴有症狀、無法手術的叢狀神經纖維瘤的1型神經纖維瘤病（NF1-PN）兒童及成人患者

EGFR 20ins二線治療戰場硝煙再起舒沃替尼全線佈局伏美替尼能否破局？| 新藥價值解碼

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/ORR/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":38.55,"timestamp":1789494649773,"preClose":38.7288,"halted":0,"volume":29765,"delay":0,"changeRate":-0.004616719340645786,"floatShares":9170000,"shares":9170000,"eps":0,"marketStatus":"交易中","change":-0.1788,"latestTime":"09-15 13:54:50 EDT","open":38.8,"high":38.8,"low":38.3,"amount":1143489.5950749998,"amplitude":0.01291,"askPrice":38.56,"askSize":600,"bidPrice":38.39,"bidSize":300,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789502400000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":38.7288,"sharesOutstanding":12900000,"nav":38.64,"aum":354328800,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":38.8756,"preClose":38.7288,"latestTime":"19:30 EDT","volume":254,"amount":9872.1379,"timestamp":1789428600910,"change":0.1468,"changeRate":0.00379,"amplitude":0.003759},"volumeRatio":1.361565,"impliedVol":0.1387,"impliedVolPercentile":0.4624},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9170000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.361565,"shares":9170000,"dividePrice":0,"high":38.8,"amplitude":0.01291,"preClose":38.7288,"low":38.3,"week52Low":30.655,"pbRate":"--","week52High":39.8,"institutionHeld":0,"latestPrice":38.55,"committee":-0.333333,"eps":0,"divideRate":0,"volume":29765,"delay":0,"ttmEps":0,"open":38.8,"prevYearClose":34.16,"prevWeekClose":38.8541,"prevMonthClose":38.77,"prevQuarterClose":36.32,"fiveDayClose":38.9958,"twentyDayClose":38.09,"sixtyDayClose":37.07},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2649617065","title":"日本橡膠期貨受空頭回補及非洲出口限制雙重因素提振走高。","url":"https://stock-news.laohu8.com/highlight/detail?id=2649617065","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649617065?lang=zh_tw&edition=fundamental","pubTime":"2026-07-06 10:38","pubTimestamp":1783305480,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PRMN","ORR","RJA","SHRT","CLSE","FTAG","EFFE","ION"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646311847","title":"和黃醫藥：凡瑞格拉替尼II期研究ORR達42.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646311847","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646311847?lang=zh_tw&edition=fundamental","pubTime":"2026-06-25 08:06","pubTimestamp":1782345960,"startTime":"0","endTime":"0","summary":"和黄医药：凡瑞格拉替尼II期研究ORR达42.50%","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606253782092633.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606253782092633.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4531","00013","ORR","BK4007","BK1587","BK4588","BK4585","HCM","BK1191","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642064469","title":"治療「癌症之王」，RAS抑制劑的「新搭檔」浮出水面","url":"https://stock-news.laohu8.com/highlight/detail?id=2642064469","media":"学术经纬","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642064469?lang=zh_tw&edition=fundamental","pubTime":"2026-06-09 18:01","pubTimestamp":1780999260,"startTime":"0","endTime":"0","summary":"胰腺癌常被称为“癌症之王”。MTAP缺失会造成癌细胞代谢状态改变，使其对PRMT5通路更加依赖，因此PRMT5抑制剂有望通过“合成致死”机制选择性打击这类肿瘤细胞。RAS抑制剂进入“组合疗法时代”RAS抑制剂的突破，本身已经是肿瘤药物研发史上的重要进展。除了daraxonrasib在胰腺癌中的关键3期数据受到关注，多项RAS抑制剂联合方案也在不同瘤种中持续推进。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-06-09/doc-iniavfst1773512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1861219969.SGD","BK4141","BK4605","LU1978683503.SGD","LU2357305700.SGD","BK4195","LU1720051017.SGD","LU0724618433.USD","LU1861220033.SGD","LU1720051108.HKD","LU1548497426.USD","IE00BZ199S13.USD","LU1861214812.USD","ON","IE00BD6J9T35.USD","LU1854104046.USD","PFS","LU0124384867.USD","ORR","LU2298322129.HKD","LU2360107325.USD","BK4585","LU0348723411.USD","LU1854103824.USD","BK4588","BK4211","IE00BFMHRM44.USD","LU1861215975.USD","BK4512"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640163781","title":"基石藥業公布一個指標：市值蒸發40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640163781","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640163781?lang=zh_tw&edition=fundamental","pubTime":"2026-06-04 22:16","pubTimestamp":1780582560,"startTime":"0","endTime":"0","summary":"2026年6月1日，基石药业（02616）在美国临床肿瘤学会（ASCO）年会上公布了核心管线CS2009——一款全球首创的程序性细胞死亡蛋白1（PD-1）、血管内皮生长因子（VEGF）、细胞毒性T淋巴细胞相关蛋白4（CTLA-4）三特异性抗体的I/II期临床进展更新数据。数据并未显示临床试验失败，市场却以大跌回应。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606043760738552.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606043760738552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0348783233.USD","09926","LU2778985437.USD","LU0417516571.SGD","LU1961090484.USD","LU2399975544.HKD","LU1794554557.SGD","LU0348767384.USD","LU0417516902.SGD","BK1574","LU0561508036.HKD","LU2476274308.USD","LU1720050803.USD","LU0540923850.HKD","LU0348784397.USD","BK4211","LU0348735423.USD","LU0348766576.USD","PFS","LU0348825331.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","ORR","IE00BPRC5H50.USD","BK4195","BK1161","LU2476274720.SGD","LU2488822045.USD","LU0417516738.SGD","LU0634319403.HKD","LU0348827113.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640902114","title":"人類抗癌關鍵性突破！RedMed新療法讓「癌王」患者生存期翻倍，死亡風險降低60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640902114","media":"华尔街见闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640902114?lang=zh_tw&edition=fundamental","pubTime":"2026-06-03 21:11","pubTimestamp":1780492276,"startTime":"0","endTime":"0","summary":"RedMed创新药Daraxonrasib在III期临床试验中将晚期胰腺癌患者中位生存期从6.7个月提升至13.2个月，死亡风险降低60%，疗效显著优于传统化疗。其创新“分子胶水”机制首次实现对活性RAS信号的广谱持续抑制，有望重塑胰腺癌治疗标准，并拓展至更多RAS驱动型癌症。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3773790","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1548497426.USD","IE00BFMHRM44.USD","BK4585","LU1854104046.USD","BK4605","BK4195","LU1720051108.HKD","LU2360107325.USD","BK4141","ON","LU0124384867.USD","LU1861215975.USD","LU1861219969.SGD","LU1861214812.USD","PFS","LU1978683503.SGD","ORR","LU1854103824.USD","LU2357305700.SGD","LU2298322129.HKD","LU1720051017.SGD","BK4512","BK4588","BK4211","IE00BD6J9T35.USD","IE00BZ199S13.USD","LU0348723411.USD","LU1861220033.SGD","LU0724618433.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640921641","title":"核心管線數據利空 基石藥業股價大跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2640921641","media":"21世纪经济报道","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640921641?lang=zh_tw&edition=fundamental","pubTime":"2026-06-03 07:00","pubTimestamp":1780441200,"startTime":"0","endTime":"0","summary":"6月1日盘前，基石药业（2616.HK）宣布核心资产CS2009（PD-1/VEGF/CTLA-4三特异性抗体）的多项关键临床进展，于美国临床肿瘤学会（ASCO）年会上通过两份壁报正式发布，涵盖一线及后线非小细胞肺癌（NSCLC）及结直肠癌（CRC）患者I/II期临床试验数据，以及晚期实体瘤患者更长随访后的成熟I期临床数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606033757998235.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606033757998235.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4213","CRC","LU0266512127.USD","LU0456854461.SGD","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640438958","title":"核心管線數據利空，基石藥業股價大跌超32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640438958","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640438958?lang=zh_tw&edition=fundamental","pubTime":"2026-06-01 18:05","pubTimestamp":1780308300,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者韩利明6月1日盘前，基石药业（2616.HK）宣布核心资产CS2009（PD-1/VEGF/CTLA-4三特异性抗体）的多项关键临床进展，于美国临床肿瘤学会（ASCO）年会上通过两份壁报正式发布，涵盖一线及后线非小细胞肺癌（NSCLC）及结直肠癌（CRC）患者I/II期临床试验数据，以及晚期实体瘤患者更长随访后的成熟I期临床数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606013756146980.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606013756146980.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0266512127.USD","LU0456854461.SGD","BK4213","CRC","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633451996","title":"Alpha Tau新型放射療法在美國完成臨床試驗患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=2633451996","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633451996?lang=zh_tw&edition=fundamental","pubTime":"2026-05-08 21:07","pubTimestamp":1778245620,"startTime":"0","endTime":"0","summary":"以色列医疗企业Alpha Tau Medical Ltd．今日宣布，其评估新型放射疗法Alpha DaRT治疗复发性皮肤鳞状细胞癌的美国多中心关键临床试验已完成全部88名患者招募。这标志着该疗法向获取美国食品和药物管理局上市前审批迈进重要阶段。Alpha DaRT疗法旨在通过靶向肿瘤内放射机制提供局部治疗。　　Alpha Tau公司首席执行官乌齐·索费尔指出，完成此次美国关键试验的患者招募是推动该疗法迈向商业化的核心环节。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-08/doc-inhxfamz4237008.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627491097","title":"核藥「狂飆」：2026年中外巨頭激戰300億美元藍海","url":"https://stock-news.laohu8.com/highlight/detail?id=2627491097","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627491097?lang=zh_tw&edition=fundamental","pubTime":"2026-04-14 12:54","pubTimestamp":1776142440,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者季媛媛2026年的春天，核药赛道没有一丝“倒春寒”的迹象。4月中旬，两则消息几乎同时引爆了全球核医学圈。一则是关于“中国原创”的崛起：百洋医药集团孵化企业瑞迪奥研发的99mTc-3PRGD2（吉伦泰）正式获批，这是全球首个用于SPECT显像的广谱肿瘤显像剂，打破了PET技术近30年的垄断。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604143704207863.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604143704207863.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["RDC","HCC","BK4161","BK4006","ORR","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624601597","title":"營收按年下降33.8%，基石藥業押注三抗管線進展如何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2624601597","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624601597?lang=zh_tw&edition=fundamental","pubTime":"2026-04-01 18:50","pubTimestamp":1775040648,"startTime":"0","endTime":"0","summary":"继2024年上半年首次实现盈利、全年财务业绩持续改善后，基石药业（2616.HK）2025年业绩再度下滑。年报显示，公司2025年实现收入2.7亿元，同比下降33.8%；年内亏损扩大至4.37亿元，较2024年的0.91亿元亏损增加3.46亿元。在业绩承压的背景下，基石药业同步披露了PD-1/VEGF/CTLA-4三特异性抗体CS2009的最新开发进展及I/II期关键临床数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604013692073178.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604013692073178.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4107","BK4588","L","BK4585","LU2487616109.SGD","LU0053666078.USD","ORR","LU0210528500.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623539793","title":"科賽優®在華獲批用於治療伴有症狀、無法手術的叢狀神經纖維瘤的1型神經纖維瘤病（NF1-PN）兒童及成人患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2623539793","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623539793?lang=zh_tw&edition=fundamental","pubTime":"2026-03-30 15:46","pubTimestamp":1774856760,"startTime":"0","endTime":"0","summary":"成为国内首个且唯一*获批用于3岁及3岁以上该患者人群的治疗药物 上海2026年3月30日 /美通社/ -- 阿斯利康宣布，中国国家药品监督管理局已正式批准科赛优，一种选择性、口服MEK抑制剂，用于3岁及3岁以上伴有症状、无法手术的丛状神经纤维瘤的1型神经纤维瘤病儿童及成人患者的治疗[1]。司美替尼已在美国、欧盟、日本、中国及其他国家/地区获批，用于治疗特定伴有症状且无法手术切除PN的 NF1 儿童患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/4922084_ZH22084_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4922084_ZH22084_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2236285917.USD","AZN","LU2456880835.USD","ORR","LU2462157665.USD","LU0320765992.SGD","BK4568","LU0058720904.USD","BK4585","LU0889565916.HKD","LU0289739699.SGD","BK4588","LU0109394709.USD","PN","LU2417539215.USD","BK4096","BK4007","LU1829250122.USD","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622846838","title":"EGFR 20ins二線治療戰場硝煙再起 舒沃替尼全線佈局伏美替尼能否破局？| 新藥價值解碼","url":"https://stock-news.laohu8.com/highlight/detail?id=2622846838","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622846838?lang=zh_tw&edition=fundamental","pubTime":"2026-03-27 15:58","pubTimestamp":1774598280,"startTime":"0","endTime":"0","summary":"　　CSCO指南的推荐级别，是连接高级别医学证据与复杂临床决策的桥梁。近日，艾力斯公告显示，公司提交的甲磺酸伏美替尼片EGFR 20号外显子插入突变NSCLC二线治疗适应症药品注册申请的办理环节已更新为“审批完毕-待制证”。与携带常见EGFR突变的患者相比，携带EGFR外显子20插入突变的患者通常预后较差。艾力斯的伏美替尼聚焦的同样为EGFR 20号外显子插入突变非小细胞肺癌二线治疗，将与舒沃替尼形成直接竞争。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-03-27/doc-inhsmhtu5367500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["OS","ORR","BK4097"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":32,"code":"91000000","status":"200"}]}}